ClinicalTrials.gg
CompletedNCT01087021QT-CabUpdated Dec 16, 2011

Effect of Cabazitaxel on the QTc Interval in Cancer Patients

A Phase 1 interventional study of Cabazitaxel (XRP6258) in Neoplasms, Malignant, sponsored by Sanofi. Completed at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-12-16.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Primary Objective:

  • To assess the potential effect on QTcF interval (QTc Fridericia) of cabazitaxel in cancer patients

Secondary Objectives:

  • To assess the effects of cabazitaxel on heart rate (HR), QT, QTcB (Bazett's correction), and QTcN (population specific correction) intervals
  • To assess the clinical safety of cabazitaxel
  • To assess cabazitaxel plasma concentrations at Cycle 1 at early timepoints (during infusion and up to 5h post end of infusion)
Read the detailed description

The main period of the study consists of a maximum of 21-day screening phase, then first 2 treatment cycles with cabazitaxel. End of main period will be Cycle 3 or 30 days after last dose if patient discontinues study after 1 or 2 treatment cycles. The duration for a patient for the main period of the study will be about 9 to 10 weeks (screening, 2 cycles).

After Cycle 2, patients will have the option to continue to receive cabazitaxel and should be followed for safety reporting until 30 days after the last dose of cabazitaxel.

02

Conditions studied

  • Neoplasms, Malignant

Browse trials for

03

In context

Neoplasms

10,824 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 45 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed solid that is or unresectable, and for which standard curative measures do not exist, and a treatment with a novel taxane agent is considered.

Exclusion criteria

Exclusion criteria:

  • Conditions with screening repolarization difficult to interpret, or showing significant abnormalities. This includes, but is not limited to: high degree AV block, pace-maker, atrial fibrillation or flutter
  • >480 msec on screening Electrocardiogram (ECG)
  • Significant hypokalemia at screening (serum potassium \<3.5 mMol/L)
  • Significant hypomagnesemia at screening (serum magnesium \<0.7 mMol/L) (Note: Patient may be enrolled after correction of these laboratory abnormalities)
  • Patient receives (and cannot discontinue), or is scheduled to receive a QT-prolonging drug

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    cabazitaxel

    At every cycle (every 3 weeks), on Day 1, patients will receive cabazitaxel, administered by intravenous (IV) infusion over 1 hour, at 25 mg/m2. An IV premedication regimen composed of up to 4 treatments (antihistamine, corticosteroids, H2 antagonist other than cimetidine at all cycles, plus palonosetron at cycle 1) will be administered before cabazitaxel infusion.

    Drug: Cabazitaxel (XRP6258)

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in QT interval corrected calculation by Fridericia method

    Time frame: Cycle 1, Day 1

Secondary outcomes

  1. Change from baseline in Heart rate, QT, QTcB (QT interval corrected calculation by Bazett method) and QTcN (QT interval with a population-specific correction formulae) intervals

    Time frame: Cycle 1, Day 1

  2. Other ECG parameters : PR, QRS intervals and ECG morphology

    Time frame: Cycle 1, Day 1

  3. Clinical safety based on adverse events, serious adverse event, laboratory assessments according to the National Cancer Institute- Common Terminology Criteria for Adverse Events v4.0 grade scaling

    Time frame: up to treatment discontinuation + 30 days over a maximum study period of 20 months

  4. Cabazitaxel plasma concentrations, Cmax and partial AUC -

    Time frame: Cycle 1, Day 1

07

Study locations

15 sites
  • Sanofi-Aventis Investigational Site Number 840006
    San Diego, California 92103, United States
  • Sanofi-Aventis Investigational Site Number 840002
    San Francisco, California 94115, United States
  • Sanofi-Aventis Investigational Site Number 840005
    Decatur, Illinois 62526, United States
  • Sanofi-Aventis Investigational Site Number 840008
    Wichita, Kansas 67214, United States
  • Sanofi-Aventis Investigational Site Number 840010
    Paducah, Kentucky 42002, United States
  • Sanofi-Aventis Investigational Site Number 840007
    Kansas City, Missouri 64128, United States
  • Sanofi-Aventis Investigational Site Number 840009
    Bethlehem, Pennsylvania 18015, United States
  • Sanofi-Aventis Investigational Site Number 840003
    Salt Lake City, Utah 84132, United States
  • Sanofi-Aventis Investigational Site Number 056002
    Bruxelles, 1200, Belgium
  • Sanofi-Aventis Investigational Site Number 056001
    Gent, 9000, Belgium
  • Sanofi-Aventis Investigational Site Number 208002
    Herlev, 2730, Denmark
  • Sanofi-Aventis Investigational Site Number 208001
    København Ø, 2100, Denmark
  • Sanofi-Aventis Investigational Site Number 528001
    Maastricht, 6229 HX, Netherlands
  • Sanofi-Aventis Investigational Site Number 752002
    Lund, 221 85, Sweden
  • Sanofi-Aventis Investigational Site Number 752001
    Uppsala, 751 85, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Apr 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2010
First posted
Mar 15, 2010
Start
Mar 2010
Primary completionActual
Apr 2011
CompletionActual
Nov 2011
Last update
Dec 16, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01087021
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 15, 2010
Start date
Mar 2010
Primary completion
Apr 2011
Completion
Nov 2011
Last update
Dec 16, 2011

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabazitaxel

Start the discussion